Lantern Pharma (LTRN) Tops Q2 EPS by 5c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.21), $0.05 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• UBS cuts KOSPI target by nearly 10% to reflect higher rates